Showing papers in "Journal of Hepatology in 2016"

TL;DR: The final purpose is to improve patient care and awareness of the importance of NAFLD, and to assist stakeholders in the decision-making process by providing evidence-based data, which also takes into consideration the burden of clinical management for the healthcare system.

TL;DR: The data show an unexpected high rate and pattern of tumor recurrence coinciding with HCV clearance and, although based in a very small cohort of patients, should be taken as a note of caution and prime a large scale assessment that exceeds the individual investigators capacity.

TL;DR: Clinicians who manage patients with NAFLD should not focus only on liver disease but should also consider the increased risk of cardiovascular disease and undertake early, aggressive risk factor modification.

TL;DR: In patients with HCV-related cirrhosis, DAA-induced resolution of HCV infection does not seem to reduce occurrence of HCC, and patients previously treated for HCC have still a high risk of tumour recurrence in the short term, despite DAA treatment.

TL;DR: HBV-related HCCs may arise on non-cirrhotic livers, further supporting the notion that HBV plays a direct role in liver transformation by triggering both common and etiology specific oncogenic pathways in addition to stimulating the host immune response and driving liver chronic necro-inflammation.

TL;DR: This Clinical Practice Guideline has been developed to assist physicians and other healthcare providers during the evaluation process of candidates for LT and to help them in the correct management of patients after LT.

TL;DR: How IL-6 pathways are involved in the physiology and pathophyiology of the liver and how these different pathways can be selectively inhibited and therapeutically exploited for the treatment of liver pathologies is described.

TL;DR: Sorafenib plus DEB-TACE was technically feasible, but the combination did not improve TTP in a clinically meaningful manner compared with DEB -TACE alone.

TL;DR: In this paper, the authors proposed EASL clinical practice guidelines for vascular disorders of the liver based on the subjects discussed during a monothematic conference in June 2012 in Tallinn.

TL;DR: All oral DAAs effectively cured HCV in patients with advanced liver disease and Viral clearance was associated with improvement in liver function within 6months compared to untreated patients.

TL;DR: Some aspects of EMT are still elusive and further studies are required to better link the clinical management of HCC with biomarkers and targeted therapies related to EMT, as well as explaining the current limiting insights into EMT by snapshot analyses of H CC tissues.

TL;DR: Using proteins with low ammoniagenic potential, leucine enriched amino acid supplementation, long-term ammonia lowering strategies and a combination of resistance and endurance exercise to increase muscle mass and function may target the molecular abnormalities in the muscle.

TL;DR: Treatment with HVP improves outcome in patients with ALF by increasing liver transplantation-free survival by attributable to attenuation of innate immune activation and amelioration of multi-organ dysfunction.

TL;DR: Geno- and phenotypic resistance testing as well as clinical data on the importance of RAVs for conventional triple therapies with sofosbuvir, simeprevir, and daclatasvir and available interferon-free DAA combinations are discussed.

TL;DR: It is suggested that antiviral therapy in patients with decompensated cirrhosis led to prolonged improvement in liver function, with no evidence of paradoxical adverse impact nor increase in liver malignancy.

TL;DR: Current knowledge, originating from fundamental and clinical research, that mechanistically links NAFLD to CVD is summarized and the impact of CVD on current clinical practice and future research in the area of NALFD are discussed.

TL;DR: A diet-induced animal model of non-alcoholic fatty liver disease (DIAMOND) that recapitulates the key physiological, metabolic, histologic, transcriptomic and cell-signaling changes seen in humans with progressive NASH is described.

TL;DR: In three distinct prospective cohorts, an unexpected high rate of hepatocellular carcinoma (HCC) recurrence after direct-acting antiviral (DAA) treatment has been suggested in a retrospective study, but an increased risk of HCC recurrence was not observed in patients who underwent curative HCC treatment including liver transplantation.

TL;DR: This review will highlight controversies and uncertainties concerning the HBV-specific B and T lymphocyte response, and propose future directions for research aimed at the generation of more efficient immunotherapeutic strategies.

TL;DR: Similar increases in liver fat and NASH are associated with a metabolically harmful saturated, ceramide-enriched liver lipidome in 'Metabolic NAFLD' but not in 'PNPLA3NAFLD', which may explain why metabolic but not PNPLA3 NAFLd increases the risk of type 2 diabetes and cardiovascular disease.

TL;DR: In this paper, the authors developed a risk score for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB).

TL;DR: The EASL Clinical Practice Guidelines (CPG) on the prevention, diagnosis and therapy of gallstones aim to provide current recommendations on the following issues.

TL;DR: The level of HBV RNA virion in serum may be associated with risk ofHBV viral rebound after withdrawal of treatment, and therefore, a potential predictive biomarker to monitor the safe discontinuation of nucleot(s)ide analogues-therapy.

TL;DR: A multicenter, nationwide study to assess the survival benefit of liver resection in hepatocellular carcinoma patients with portal vein tumor thrombosis using propensity score-based matching revealed that LR provides a survival benefit regardless of age, etiology of HCC, tumor marker elevation, and tumor number.

TL;DR: The multifaceted impact of NAFLD on liver transplantation is reviewed and the alternative management and therapeutic options to improve the long-term outcomes with particular emphasis on the correction and control of metabolic comorbidities are discussed.

TL;DR: After 24weeks of treatment with myrcludex B and/or pegylated interferon α-2a, HDV R NA, a relevant marker for hepatitis D infection, decreased in all patients with chronic hepatitis B and D.

TL;DR: An overview of the HBV life cycle is provided, followed by review of HBV genotypes and mutants in terms of their biological properties and clinical significance.

TL;DR: LSM and FibroMeter(V2G) fibrosis classifications help physicians estimate both fibrosis stage and patient prognosis in clinical practice and were the two most accurate tests for the non-invasive evaluation of liver fibrosis in NAFLD.

TL;DR: This study shows for the first time that the DAAs may lead to a remarkable clinical improvement allowing the delisting of one patient out of 5 in 60weeks, respectively.